Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients
Video navigation menu
- The EMPA-REG CV OUTCOME trial of empagliflozin 0:00
- Heart failure outcomes in the EMPA-REG OUTCOME trial 1:46
- Does presence of HF at baseline drive the HF outcomes? 2:15
- What do these results mean for use of diabetes medication in high-risk individuals? 2:58
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.